Chidamide to Prevent AML Return After Bone Marrow Transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 65 years old when you sign consent
- You had an allo-HSCT for AML and are in complete remission
- Your blood counts have recovered after transplant (neutrophils and platelets meet study thresholds)
- You do not have leukemia in the brain/spinal fluid and have no related symptoms after transplant
- You have no serious ongoing problems with key organs and no active uncontrolled infections
- You can sign consent and complete required study tests; if you can become pregnant, you must use birth control and have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
This study tests a maintenance drug called chidamide, which may help keep your T-cell leukemia or lymphoma from returning after a stem cell transplant. You will take this drug as a pill to see if it extends the time you stay cancer-free.
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
This trial tests a pill called chidamide for people with a bone marrow condition called myelodysplastic syndromes (MDS). It may help improve blood counts and reduce the need for transfusions.
This Phase 2 study tests whether azacitidine can improve outcomes when donor blood “chimerism” starts dropping after an allogeneic stem cell transplant. It’s for people with AML, MDS, MPN, or CMML who are experiencing early warning signs in their blood counts after transplant but without clear relapse in the bone marrow.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.